StockPicking.com traders look to Pfizer to trend higher on Covid-19 Vaccine.
Pfizer Inc. (PFE) - Email Alert - 11/09/20 - 8:00 AM EST
We are placing an alert on Pfizer Inc. (PFE). The stock closed Friday at $36.40 a share and in our opinion is going higher. The COVID-19 vaccine being developed by Pfizer and its partner BioNTech has shown to be effective blocking vaccine in 90 percent of participants in its Phase 3 clinical trial, the companies announced on today. Based on data analyzed by an external, independent committee assigned to check the results of the trial, and reflects only early results from the trial, and not the final verified result, but it's still extremely promising news for progress towards a viable and more broadly available vaccine. Since this has a slight bit of speculation involved, investors should consider this when investing. In addition to the vaccine, Pfizer has 92 drugs in the pipeline with 6 in registration, 21 in Phase 3, 36 in Phase 2, and 29 in Phase 1.
SHORT-TERM PRICE TARGET
Vaccine 90% effectiveness in studies
OUR SHORT-TERM TARGET PROBABILITY RATING 1-10
10/27/20 - Pfizer (PFE) reported 3rd Quarter September 2020 earnings of $0.72 per share on revenue of $12.1 billion. The consensus earnings estimate was $0.70 per share on revenue of $12.3 billion. The Earnings Whisper number was $0.77 per share. Revenue fell 4.3% compared to the same quarter a year ago.
The company Pfizer, Inc. PFE said it expects 2020 earnings of $2.88 to $2.93 per share on revenue of $48.80 billion to $49.50 billion. The company's previous guidance was earnings of $2.85 to $2.95 per share on revenue of $48.60 billion to $50.60 billion and the current consensus earnings estimate is $2.90 per share on revenue of $49.19 billion for the year ending December 31, 2020.
The stock has a 52 week high of $40.97 and a low of $27.88. Support is around $35 a share and should be a good location for a protective sell stop order or self-imposed sell alert.
Pfizer Inc. develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and pain under the Eliquis, Chantix/Champix, and Premarin family brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Sutent, Xtandi, Xalkori, Inlyta, Braftovi + Mektovi brands; and sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Vfend, and Zithromax brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, and tick-borne encephalitis under the Prevnar 13/Prevenar 13 (pediatric/adult), FSME-IMMUN, Nimenrix, and Trumenba brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, and Eucrisa brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, Genotropin, and Refacto AF/Xyntha brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration and/or co-promotion agreements with Bristol-Myers Squibb Company and Astellas Pharma US, Inc.; a licensing agreement with Akcea Therapeutics, Inc; a strategic alliance with Verily Life Sciences LLC; collaboration agreements with Merck KGaA and Valneva SE; a clinical trial collaboration and supply agreement with IDEAYA Biosciences, Inc.; a material transfer and collaboration agreement with BioNTech SE; a clinical supply collaboration with Jiangsu Alphamab Biopharmaceuticals Co., Ltd; a research collaboration and license agreement with BioInvent International AB; and a multi-target drug discovery collaboration with Sosei Group Corporation. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.